“Early treatment may help people avoid disease progression and avoid hospitalization,” Janet Woodcock, director of the Food and Drug Administration’s Center for Drug Evaluation and Research, said on a conference call along with Azar. The FDA on Monday gave emergency use authorization to Lilly’s antibody for anyone over age 65 who is recently diagnosed with mild-to-moderate COVID-19, and for patients age 12 and older who have an underlying health condition putting them at risk for serious illness.
